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is projected to be cost-savings against PR alone in the majority of CHC genotype 
1 patients, regardless of treatment history.
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Objectives: Economical evaluation of Stribild in Turkey, which is a single tablet 
regimen indicated for the treatment of HIV-1 infection in adults aged 18 years and 
over who are antiretroviral treatment naive or are infected with HIV-1 without 
known mutations associated with resistance to any of the three antiretroviral agents 
in it. MethOds: STRIBILD™ was compared with various treatment options; teno-
fovir DF+emtricitabine+efavirenz (FTC/TDF+EFV), tenofovir DF+emtricitabine+ 
ritonavir+lopinavir (FTC/TDF+LPV/r), tenofovirDF+emtricitabine+nevirapine (FTC/
TDF+NVP), tenofovir DF+emtricitabine+darunavir (FTC/TDF+DRV+r), tenofovir 
DF+emtricitabine+raltegravir (FTC/TDF+RAL), lamivudine+zidovudine+efavirenz 
(3TC/AZT+EFV), lamivudine+zidovudine+ritonavir+lopinavir (3TC/AZ+LPV/r), lam
ivudine+zidovudine+nevirapine (3TC/AZT+NVP). The adherence rates were calcu-
lated from the increase rate in CD4 cell count and the risk of hospitalization as 
the effectiveness values. The data were taken from patient files from Hacettepe 
University that consists of 252 patients and 12 year follow-ups with an outpatient 
clinic, interventions, laboratory and imaging tests, medication usage, side effects, 
comorbidity’s diseases and their treatments and complications. The costs of treat-
ment of diseases were calculated by cost of disease methodology. Average annual 
cost per patient is calculated for health care technologies. Health technology effec-
tiveness values are found from the literature review. Incremental cost-effectiveness 
ratio (ICER) was used for the comparison. Results: According to comparison of rate 
of compliance to treatment, STRIBILD™ was cost effective against 3TC/AZT+EFV 
(2157.2 TL), FTC/TDF+LPV/r (612.7 TL), FTC/TDF+NVP (951.9 TL), FTC/TDF+DRV+r 
(544.28 TL) and cost saving aganist FTC/TDF+RAL (-166,22 TL). According to the rate 
of risk of hospitalization, STRIBILD™ was cost effective against 3TC/AZT+EFV (517.7 
TL), FTC/TDF+LPV/r (318.6 TL), FTC/TDF+NVP (495 TL), FTC/TDF+DRV+r (283 TL), 3TC/
AZT+EFV (632,4 TL), 3TC/AZ+LPV/r (425.6 TL), 3TC/AZT+NVP (591.2 TL). According to 
the increase rate in CD4 cell count and over 95% of compliance rate, STRIBILD™ was 
cost effective against FTC/TDF+EFV (392.2 TL) and cost saving against FTC/TDF+RAL 
(-308.7 TL), respectively. cOnclusiOns: HIV is a life-threatening disease with in 
terms of major public health problem globally.. In this study, STRs in comparison 
of combination treatment strategies, has higher compliance rates, better outcomes 
and lower health care costs.
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Objectives: The objective was to assess the cost-effectiveness of 3 scenarios for the 
diagnosis of TB among PLWH depending on CD 4+ count and their influence to treat-
ment pathway and outcomes. MethOds: A deterministic decision analytic model 
was designed for three TB possible searching scenarios in three hypothetical cohorts 
of 1000 PLWH with different CD 4+ count (< 200, 200-499, > 500). The following scenar-
ios were examined: ‘‘Base’’— the current diagnostic scheme, according the National 
Program; ‘‘Addition’’—the current diagnostic scheme and Xpert/Rif; ‘‘Replacement’’ 
– Xpert/Rif test only. Inputs’s from the country report and Russian epidemiologic 
data. The analysis was conducted from the Russia health care perspective with an 
analytic horizon of 2 years. Results: CD 4+ < 200 cohort CER in “Base” is 541817, 
in “Addition” – 643771, “Replacement” – 648087. Additional cost per one success-
fully treated RUB1123K (23893 € ), cost per death averted pts RUB5035K (107127 € ), 
in “Addition” compared to “Base”. CD 4+ 200 – 499 cohort CER in “Base” is 390693, 
in “Addition” – 550615, “Replacement” – 665529. Additional cost per one success-
fully treated RUB5422K (115361 € ), cost per death averted pts RUB5226K (111191€ ) 
in “Addition” compared to “Base”. CD 4+ > 500 cohort CER in “Base” is 408581, in 
“Addition” – 642137, “Replacement” – 597470. Additional cost per one success-
fully treated RUB6093K (129638 € ), cost per death averted pts RUB6649K (141468 € ) 
in “Addition” compared to “Base”. cOnclusiOns: If it needs to solve, which of 
diagnostic scenarios we finance, we should take into account not only CER, but 
opportunity to miss TB cases. Using “Addition” is especially effective for diagnostic 
research in CD 4+ < 200 cohort.
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Objectives: Single-Tablet Regimens (STR) therapies are effective to maintain high 
adherence and improves HAART efficacy. MethOds: We evaluated viro-immunologic 
outcomes, Quality of Life (QoL), and costs of an unselected cohort of patients switch-
ing from TDF/FTC/EFV STR (≥ 6 months duration) to TDF/FTC/RPV STR. The considered 
outcome measures were quality-adjusted life years (QALYs) as measured with the 
EQ5D questionnaire and the overall direct health costs. 64 patients with a baseline 
viral load < 50 copies/ml were randomized to immediately switch therapy or to con-
tinue TDF/FTC/EFV for 4 months and then switch to TDF/FTC/RPV. 6 patients in the 
deferred switch group did not change cART. Results: Patients were mostly males 
(73.4%) with a mean age of 46 years, a baseline mean HIV-RNA of 6.42 copies/ml and 
a mean baseline CD4 count of 588 cells/μ L. The mean cost per patient resulted € 2,563 
for STR with RPV arm and € 2,572 for STR with EFV arm. After 4 months the mean 
Objectives: Since 2009, 12-year-old Dutch teenage girls are vaccinated against 
human papillomavirus (HPV) infection. The current uptake of HPV vaccination, being 
approximately 60% nowadays, is however comparatively low. Consequently, a large 
group of women are still at risk of developing HPV-induced cervical cancer later on in 
life. Therefore, alternative HPV vaccination scenarios have been proposed, in addition 
to the existing programme, to provide additional protection against cervical cancer. 
Here, we assessed the cost-effectiveness of three different vaccination scenarios: (i) 
increased coverage of the existing programme, (ii) vaccination of girls at an older age, 
and (iii) vaccination of 12-year-old boys. MethOds: A dynamic model was used to 
estimate the full health-economic consequences of the existing programme with 
and without the above alternative scenarios. Costs and health effects of the alterna-
tive scenarios, expressed as life years (LYs) or quality-adjusted life years (QALYs) 
gained, were compared with the outcomes of the existing programme. In sensitivity 
analyses, the robustness of the model-predicted outcomes was evaluated. Results: 
We found the incremental cost-effectiveness ratio of the existing HPV vaccination 
programme to be € 9,500 per QALY gained. The cost-effectiveness of the alternative 
programs highly depends on the coverage at 12 years of age. The cost-effectiveness 
of girls 24 years of age remained below € 50,000/QALY if coverage at 12 years of age 
increased up to 70%. Cost-effectiveness of vaccination boys at 12 years of age becomes 
unfavourable if coverage among 12-year old girls increases. cOnclusiOns: From a 
health-economic perspective, alternative HPV vaccination programmes should be 
considered in the Netherlands to further reduce the burden of HPV-induced cancer. 
Until a high coverage among 12-year old girls in reached the addition of older girls to 
the current vaccination program is most cost-effective.
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Objectives: Utilization of routine viral load (VL) and CD4 cell count coupled to clini-
cal monitoring of HIV patients needs to be carefully deliberated in cost-effective-
ness, especially for resource-limited countries. The review was aimed to evaluate 
and compare the cost-effectiveness of these strategies individually and in combina-
tion. MethOds: A literature review was conducted for studies published in English 
from 2004 to 2014 on Pubmed, Web of Science, Ovid, Google Scholar, with keywords 
HIV, viral load, CD4, economic evaluation, and cost analysis. All underwent assign-
ment of Levels of Evidence (LOE) by Oxford Center for Evidence-Based Medicine 
(CEBM), as well as Drummond scoring criteria. Results: Thirty English publications 
were identified, including 14 modeling studies, 7 randomized clinical trials (RCT’s), 
and 5 cohort studies among others. A total of 24 were based on resource-limited 
settings such as Africa, Latin America, and Asia. Compared with CD4, VL alone had 
incremental cost-effectiveness ratios (ICER’s) ranging from $2520/LY to $3570/life year 
(LY); while that of CD4 alone compared to clinical monitoring was from $-13134/LY 
to $5768/quality-adjusted life year (QALY). The combination of CD4 and VL, which is 
recommended in real-life practice, compared to CD4 alone yielded ICER’s ranging from 
$3956/QALY to $16139/QALY. The cost-effectiveness of these strategies was affected 
by factors such as the reference threshold for ICER, costs and monitoring regimens 
of the strategies and antiretroviral treatment. cOnclusiOns: From the studies, it 
is critical to evaluate the cost-effectiveness of CD4 compared with VL contextually, 
with CD4 being more appropriate in resource-limited settings. VL is associated with 
improved benefit, however when used in combination with CD4, is usually not cost-
effective. Compared with clinical monitoring alone CD4 usually produces greater 
cost-effectiveness.
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Objectives: Current Thai guidelines reimburse peginterferon/ribavirin (PR) com-
bination treatment for patients infected with all genotypes of chronic hepatitis 
C (CHC), based on the results of cost-effectiveness studies. Two trials, SPRINT-2 
and RESPOND-2, have demonstrated that treatment with Boceprevir (BOC) in 
addition to PR results in significantly higher sustained virologic response rates 
than the current standard of care, PR alone for 48 weeks, in both treatment naïve 
and treatment experienced CHC genotype 1 patients. The aim of our analysis 
was to evaluate the cost-effectiveness of BOC-based treatment compared with 
PR alone from the perspective of the policy maker in Thailand over a lifetime 
horizon. MethOds: A decision analytic model was developed to simulate the 
treatment strategies described in the BOC label (BOC/PR) and PR alone, and to 
describe the natural history of CHC to make projections beyond the treatment 
phase. Separate analyses were conducted based on patients’ treatment history 
and cirrhosis status. Patient characteristics were obtained from SPRINT-2 and 
RESPOND-2. Treatment characteristics including efficacy and the rate of side 
effects were obtained from subset analyses of these trials. Transition probabili-
ties, costs, and health state utilities were obtained from previously studies. We 
projected the lifetime cumulative incidence of CHC-related liver complications 
– decompensated cirrhosis, hepatocellular carcinoma, liver-transplantation, liver-
related mortality - discounted costs and QALYs associated with each treatment 
strategy. The incremental cost-effectiveness ratio was also assessed. Results: 
For treatment naïve and treatment experienced patients, BOC/PR treatment is 
projected to reduce the incidence of CHC-related liver complications by 43-44% 
and 47-51%. BOC/PR is projected to be less expensive and result in increases of 
0.13-2.62 QALYs for all non-cirrhotic patients and cirrhotic treatment-experienced 
patients. Cirrhotic treatment naïve patients was the only subgroup in which cost-
effectiveness was not demonstrated. cOnclusiOns: In the Thai setting, BOC/PR 
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(QIV), comparing to TIV, in age-stratified populations of Hong Kong from 2001-2010 
years. MethOds: TIV-unmatched influenza B infection rates with QIV versus TIV 
were estimated by an epidemiology model. Model parameters included percentages 
of influenza B lineages in circulation, influenza B-associated hospital admission, 
age-specific population, vaccine coverage and effectiveness. Events (outpatient 
care, hospitalizations and death) caused by infection of the influenza B lineage 
not included in TIV coverage in each year were calculated. Cost savings and QALYs 
gained from reduced events with QIV were estimated. Incremental cost per QALY 
gained (ICER) by QIV versus TIV were estimated from Hong Kong’s societal perspec-
tive. Results: All-age mean reduction in influenza B infection rate (per 100,000) 
was 25.9 (95%CI 6.7-45.1). Highest age-specific rate reduction was 451.4 (95%CI 87.7-
815.1) in ≥ 80 years, followed by 104.8 (95%CI 27.2-182.4) in 65-79 years and 13.2 
(95%CI 7.0-19.4) in 6 months-4 years. Highest cost savings and QALY gain occurred 
in years with high percentage (81.8%-96.4%) of circulated influenza B lineage not 
covered by TIV. QIV was more cost-effective than TIV in 6 years when it cost USD1 
more than TIV. When QIV was USD2, USD5 and USD10 more costly, it became cost-
effective in 3, 3 and zero years, respectively. cOnclusiOns: QIV was cost-effective 
in very young and older populations. Cost-effectiveness of QIV was subjected to unit 
cost of QIV versus TIV and percentage of circulating influenza B lineages.
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Objectives: Hong Kong is a developed city with intermediate tuberculosis (TB) 
burden of 90 per 100,000 population and low HIV prevalence. The diagnosis of TB 
in hospitalized patients was difficult due to atypical manifestation and low sen-
sitivity of sputum acid-fast bacilli (AFB) smear microscopy examination. Failure to 
receive early anti-TB treatment during initial assessment was identified to be an 
independent predictor associated with increased risk of mortality. We examined the 
cost-effectiveness of rapid diagnosis with Xpert MTB/RIF in patients hospitalized for 
suspected active pulmonary tuberculosis (PTB) from the perspective of Hong Kong 
public health care providers. MethOds: A decision tree was designed to simulate 
outcomes of three diagnostic assessment strategies in adult patients hospitalized 
for suspected active PTB: conventional approach, sputum smear plus Xpert for AFB 
smear-negative, and a single sputum Xpert test. Model inputs were derived from 
literature. Outcome measures included direct medical cost, one-year mortality rate, 
quality-adjusted life-years (QALYs) and incremental cost per QALY (ICER). Results: 
In base-case analysis, one-year mortality rate of the Xpert group was 9.0% with 8.289 
QALYs gained. Comparing to smear plus Xpert, the Xpert group was more effective by 
an ICER of USD99. Conventional approach was the least preferred option with highest 
cost, lowest QALYs gained and highest mortality rate. Sensitivity analysis showed that 
Xpert would be the most cost-effective option if the sensitivity of sputum AFB smear 
microscopy was 74% or less. In 10,000 Monte Carlo simulations, the probabilities of 
Xpert, smear plus Xpert and conventional approach to be cost-effective were 94.5%, 
5.5% and 0%, respectively. cOnclusiOns: Xpert sputum test appears to be a highly 
cost-effective diagnostic strategy for patients with suspected active PTB in intermedi-
ate burden area like Hong Kong.
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Objectives: To estimate the cost effectiveness ratio of a inactivated quadrivalent 
influenza vaccine compared to the trivalent ones in France. MethOds: During 
some epidemic influenza seasons a mismatch between the circulating B strains 
and the one included in the trivalent vaccine is observed. The difference of vaccine 
protection by the quadrivalent vaccine due to the inclusion of both circulating B 
strains should avoid the occurrence of a number of consultations and complications 
resulting in hospitalizations and deaths. A decision tree model was built to compare 
the efficacy and costs of the two vaccines for an average epidemic influenza season 
in the French setting. The number of hospitalization and deaths associated with 
influenza were estimated from an analysis of available French data. Estimates of 
these medical events were calculated using French standard costs in 2012 and obser-
vational data. Deterministic and probabilistic sensitivity analyses (PSA) were con-
ducted. Results: The base case analysis considered the global French vaccinated 
population during an average epidemic season between seasons 03/04 and 11/12 
with a B circulating virus rate of 23% and a mismatch rate of 58%. The perspective is 
collective. The number of avoided consultations for influenza was estimated at 6,214 
and the number of avoided hospitalizations and deaths at 614 and 372 respectively. 
The number of life years gained (LYG) was estimated at 5,382. The cost per LYG was 
estimated at 3,138€ /LYG. Sensitivity analyses showed clearly the importance of the 
B circulating virus rate combined with the mismatch rate highly variable according 
to influenza seasons. PSA showed that 100% of estimates in the acceptability curve 
were under 20,000€ per LYG in the base case analysis. cOnclusiOns: The cost 
effectiveness ratio of an inactivated quadrivalent influenza vaccine compared to 
trivalent ones in the French setting can be considered acceptable.
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per patient QALYs was 0.849 and 0.841 respectively. Viremia remained undetectable 
and CD4 stable in all patients. Additionally, other parameters such as Cholesterol, 
HDL and Triglycerides levels improved when switching from STR-containing EFV to 
Rilpivirine-based STR. VAS analysis of health status perception also increased over-
all from 82.78 to 83.79 (scale: 0-100) due to the improvement in the STR-containing 
RPV arm. STR with RPV dominated (i.e. was more effective and less costly) EFV STR 
regimen, as measured by outcomes. cOnclusiOns: Switching from STR containing 
Efavirenz to STR containing Rilpivirine is a safe, well tolerated strategy that improves 
the overall health status of HIV–treated patients. The switch does not expose patients 
to a risk of virologic failure due to possible PK interactions of the drugs. RPV compared 
to EFV resulted cost-effective showing lower cost and higher outcome measure values.
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Objectives: HIV is a life-threatening disease in terms of a major global public health 
problem. This analysis evaluates the cost-effectiveness comparison of HIV-1 treatment 
alternatives including lamivudine+zidovudine+efavirenz (3TC/AZT+EFV), tenofovir 
DF+emtricitabine+efavirenz (FTC/TDF+EFV), tenofovir DF+emtricitabine+ritonavir+ 
lopinavir (FTC/TDF+LPV/r), tenofovir DF+emtricitabine+ darunavir (FTC/TDF+ DRV+ 
r), and elvitegravir+cobicistat+emtricitabine+tenofovir DF (STRIBILD). MethOds: This 
analysis compares the HIV treatment alternatives of 3TC/AZT+ EFV, FTC/TDF+EFV, FTC/
TDF+LPV/r, FTC/TDF+DRV+ r and STRIBILD. The adherence rates were calculated from 
the increase rate in CD4 cell count and the risk of hospitalization as the effectiveness 
values. The data were taken from patient files from Hacettepe University that consists 
of 252 patients and 12 year follow-ups with an outpatient clinic, interventions, labora-
tory and imaging tests, medication usage, side effects, comorbidity’s diseases and their 
treatments and complications. The costs of treatment of diseases were calculated by 
cost of disease methodology. Average annual cost per patient is calculated for health 
care technologies. Health technology effectiveness values are found from the literature 
review. Virological response success is used from clinical studies as an end-point for 
this analysis. The treatment cost comparison is calculated with the incremental cost 
effectiveness-ratio (ICER). Results: Results of the clinical effectiveness of the treat-
ment alternatives of 3TC/AZT+ EFV, FTC/TDF + EFV, FTC/TDF +LPV/r, FTC/TDF+ DRV+ 
r and STRIBILD were 58%, 75%, 78%, 84%, and 88%, respectively. In the cost -effective-
ness comparison analysis, the annual total treatment costs are calculated as 12531 
TL, 17524 TL, 24284 TL, 22987 TL, and 20868 TL, respectively. The total ICER analysis 
shows only STRIBILD, FTC/TDF+EFV and 3TC/AZT+EFV treatments are cost-effective, 
while the other treatment alternatives are not cost-effective. cOnclusiOns: The HIV-1 
treatment study was conducted in Turkey on the cost-effectiveness of this treatment 
strategy. The clinical efficacy and the cost-effectiveness of STRIBILD shows that it is an 
effective treatment strategy for HIV patients.
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Objectives: To perform comparative pharmacoeconomic analysis of ertapenem in 
patients with community-acquired complicated intraabdominal infection in com-
parison with alternative therapy moxifloxacin. MethOds: Were reviewed research 
on the clinical effectiveness and safety of use of ertapenem to prevent postoperative 
inflammatory complications and lethal outcomes. Assess of the quality of research 
and level of evidence obtained in these results was performed. The results of the 
research PROMISE formed the basis of pharmacoeconomic model. The effectiveness 
of therapy in studies was assessed by the frequency of clinical and bacteriological 
success of treatment with the use of different modes of antibacterial therapy. We 
calculated the difference in direct medical costs for treatment by ertapenem and 
moxifloxacin and cost-effectiveness ratio. Results: According to a study J. J. De 
Waele et al., in patients treated with ertapenem, the frequency of clinical effect of 
treatment was higher than in the group of patients receiving moxifloxacin: 93,4% 
and 89.5%, respectively. The mortality rate associated with the development of 
severe sepsis, was also lower for ertapenem: 3,1% and 5.4% respectively. Direct 
medical costs accounted in the group of moxifloxacin with the average duration 
of therapy is 7 days was 1798 USD, in the group of ertapenem with the average 
duration of treatment 6.8 days - 1981 USD. When using moxifloxacin instead of 
ertapenem ICER for one additional prevented complication was 4688 USD, and for 
one surviving patient - 17027 USD. One way sensitivity analyses showed that the 
results of the model were not sensitive to changing the cost of ertapenem from 75% 
to 125 %. cOnclusiOns: Pharmacoeconomic analysis showed that the application 
of ertapenem for the treatment of community-acquired complicated intra-abdom-
inal infections is expensive but more efficient and economically justified strategy.
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Objectives: The seasonal trivalent influenza vaccine (TIV) covers two subtypes 
of influenza A (A/H1N1 and A/H3N2) plus one of the two influenza B lineages cir-
culating in humans. Co-circulation of both influenza B lineages (B/Victoria and 
B/Yamagata) was common in Hong Kong. We examined the difference in costs 
and quality-adjusted life-years (QALYs) gained by quadrivalent influenza vaccine 
